Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy.

Abstract

Although TNM staging based on tumor, node lymph status and metastasis status-is the most widely used method in the clinic to classify breast cancer (BC) and assess prognosis, it offers limited information for different BC subgroups. Circulating tumor cells (CTCs) are regarded as minimal residual disease and are proven to have a strong relationship with BC. Detection of ≥5 CTCs per 7.5 mL in peripheral blood predicts poor prognosis in metastatic BC irrespective of other clinical parameters, whereas, in early-stage BC, detection of CK19(+) CTCs are also associated with poor prognosis. Increasing data and clinical trials show that CTCs can improve prognostic accuracy and help tailor treatment for patients with BC. However, heterogeneous CTCs in the process of an epithelial-mesenchymal transition (EMT) in BC makes it a challenge to detect these rare cells. Moreover, the genotypic and phenotypic features of CTCs are different from primary BC tumors. Molecular analysis of CTCs in BC may benefit patients by identifying those amenable to tailored therapy. We propose that CTCs should be used alongside the TNM staging system and the genotype of primary tumor to guide tailored BC diagnosis and treatment.

• Authors: Chuanli Ren, Chongxu Han, Deyuan Fu, Daxin Wang, Hui Chen, Yong Chen, Ming Shen
• Journal: International journal of cancer (Int J Cancer) Vol. 138 Issue 7 Pg. 1586-600 (Apr 01 2016) ISSN: 1097-0215 [Electronic] United States
• PMID: 26178386 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2015 UICC.

Topics

• Animals
• Breast Neoplasms (blood, genetics, pathology)
• Female
• Genotype
• Humans
• Neoplasm Staging (methods)
• Neoplastic Cells, Circulating (pathology)